Aeglea BioTherapeutics Announces Leadership Change July 20, 2017

Aeglea BioTherapeutics Announces Leadership Change

view full story

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts July 17, 2017

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts.

view full story

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer July 10, 2017

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

view full story

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry July 5, 2017

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

view full story

Aileron Therapeutics Announces Pricing of Initial Public Offering June 28, 2017

Aileron Therapeutics Announces Pricing of Initial Public Offering

view full story

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency June 20, 2017

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

view full story

Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts June 19, 2017

Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts

view full story

Coherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate) June 12, 2017

Coherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate)

view full story

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species June 5, 2017

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species

view full story

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis June 4, 2017

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

view full story

Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924 June 3, 2017

Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924

view full story

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease May 30, 2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

view full story

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 May 25, 2017

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

view full story

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update May 23, 2017

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

view full story

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update May 22, 2017

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update

view full story

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee May 18, 2017

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee

view full story

Coherus Biosciences prevails in ‘135 IPR decision May 16, 2017

Coherus Biosciences prevails in ‘135 IPR decision

view full story

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week April 20, 2017

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

view full story

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation April 10, 2017

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.

view full story

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel April 6, 2017

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment

view full story

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy April 3, 2017

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

view full story

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102 March 29, 2017

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting

view full story

Aeglea Biotherapeutics to Present Topline Data March 23, 2017

Aeglea Biotherapeutics to Present Topline Data from Phase 1 Trial of AEB1102

view full story

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer March 17, 2017

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer

view full story

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint March 2, 2017

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint

view full story

Symic Bio Announces Last Patient Enrolled in SHIELD Trial February 24, 2017

Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease

view full story

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson's research February 21, 2017

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson’s research

view full story

Protagonist Therapeutics Presents Data on Oral Peptide February 17, 2017

Protagonist Therapeutics Presents Data on Oral Peptide

view full story

Coherus prices public offering of common stock February 8, 2017

Coherus prices public offering of common stock

view full story